A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
for Solid Tumor
24 locations incl. Tucson
Sponsor: Eisai Inc.
Sex: All·Age: 18+
Code: NCT04300556·Phase 1, Phase 2·Recruiting